◀ Back to AHSA1

AHSA1 — PTGS2

Text-mined interactions from Literome

Hirai et al., Thromb Haemost 1999 (MAP Kinase Signaling System) : These data indicate that PMA induced and PKC dependent expression of COX-2 requires mainly activation of ERK 1/2 among MAPKs, while activation of both ERK1/2 and p38 or possibly of all three families of MAPKs is necessary for vanadate induced and PTK dependent expression of COX-2
Paik et al., J Biol Chem 2000 (Adenocarcinoma...) : The inhibitor of extracellular signal regulated protein kinase, p38 , or NFkappaB does not affect the NSAID induced COX-2 expression
Cheng et al., J Clin Invest 2000 : Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride
Scheuren et al., J Mol Cell Cardiol 2002 (Necrosis) : The p38 mitogen activated protein kinase ( MAPK ) inhibitor SB203580 but not the p42/44 MAPK-inhibitor PD98059 suppressed Ang II-induced COX-2 protein expression
Bachelor et al., Oncogene 2002 (Skin Neoplasms) : The role of p38 in UVA induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT
Gardner et al., FASEB J 2003 (Lung Neoplasms) : Furthermore, the p38/MAPK inhibitor, SB203528, and the p42/44 inhibitor, PD98059, blocked methanandamide mediated induction of PGE2 and COX-2
Grab et al., Biochim Biophys Acta 2004 : The ERK and p38 MAPKs can also stimulate the expression of both cyclooxygenase-2 (Cox-2) and interleukin-8 (IL-8)
Gauthier et al., Cancer Res 2005 (Breast Neoplasms...) : p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue
Lim et al., FEBS Lett 2005 : The p38 MAPK inhibitor, SB203580, or MEK1/2 inhibitor, U0126, inhibited hypertonic induction of COX-2 expression
Duggan et al., J Cell Physiol 2007 : GF109203X did not affect MAPK activities, and neither did it replicate the effect of p38 MAPK inhibition on Cox-2 mRNA stability, suggesting that PKC operates through an independent mechanism
Pham et al., J Cell Physiol 2008 : The p38 ( MAPK ) selective inhibitor, SB202190, but not the MEK selective inhibitor, PD98059, or the EGFR kinase inhibitor, AG1478, inhibited Ang II-dependent COX-2 expression and CREB phosphorylation
Eckert et al., Vet Immunol Immunopathol 2007 : We tested our hypothesis by investigating the effects of the specific p38 MAPK inhibitors SB203580 and SB202190 on LPS induced COX-2 protein expression and PGE ( 2 ) production in equine leukocytes
Gallicchio et al., Br J Pharmacol 2009 : We found that mainly p38 , p42 and p46 MAPKs were phosphorylated by SP and SB202190, PD98059 and SP600125, which are selective inhibitors of these kinases, blocked SP-induced COX-2 expression
Stitt-Cavanagh et al., J Am Soc Nephrol 2010 (Albuminuria) : Previously, we identified a feedback loop in podocytes whereby an in vitro surrogate for glomerular capillary pressure ( i.e., mechanical stretch ) along with prostaglandin E ( 2 ) stimulation of its EP4 receptor induced cyclooxygenase-2 in a p38 dependent manner
Akhtar et al., Ann Rheum Dis 2012 (Osteoarthritis) : Activation of p38-MAPK downregulated the expression of miR-199a* and induced COX-2 expression
Pouliot et al., Blood 1998 : Similarly, an inhibitor of the p38 mitogen activated protein kinase, SB 203580, inhibited the stimulation of COX-2